Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer
When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.
When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.
The antibody drug conjugate, T-DM1, when used alone or in combination with pertuzumab, did not significantly improve overall survival compared with trastuzumab and a taxane.
A study showed that symptom monitoring by integrating electronic patient-reported outcomes into clinical practice vs usual care extended OS by more than 5 months.
Data from PALOMA-1/TRIO-18 showed that combining palbociclib and letrozole did not significantly improve survival compared with letrozole alone among patients with breast cancer.
Patients with breast cancer who progress on endocrine therapy and are then treated with abemaciclib and fulvestrant have a 45% decreased risk for progression.
Aldoxorubicin significantly prolongs PFS and provides better objective response rates than investigators’ choice of treatment or standard of care in the treatment of soft tissue sarcoma.
Consuming Korean red ginseng was reported to improve cancer-related fatigue among Korean patients with colorectal cancer (CRC) treated with FOLFOX.
Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment.
A retrospective analysis of next-generation sequencing profiles has diagnostic and therapeutic implications for patients with soft-tissue or bone sarcoma.
The landscape of complex genetic mutations in sarcomas seen through next-generation sequence profiling provides a rationale for a study to match patients to the appropriate therapy.